A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Official Title

A Phase 3, Multicentre, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors

Summary:

This is a Phase 3, multicentre, randomized, double blind, placebo-controlled study
evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in
subjects with relapsed or refractory multiple myeloma who are considered sensitive or naïve
to proteasome inhibitors and received 1 to 3 prior lines of therapy for multiple myeloma.